Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease

BACKGROUND: The ability of unstandardized methods to track kidney growth in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) has not been critically evaluated. METHODS: The Tolvaptan Efficacy and Safety Management of ADPKD and its Outcomes (TEMPO) 3:4 study involved baseline...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Kidney J
Auteurs principaux: Edwards, Marie E, Blais, Jaime D, Czerwiec, Frank S, Erickson, Bradley J, Torres, Vicente E, Kline, Timothy L
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Familial Nephropathies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366146/
https://ncbi.nlm.nih.gov/pubmed/30746130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy078
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires